Evidence On What Works In Regulating Health And Social Care - The King's Fund

It is a dietary staple found in sushi, rice wraps and ramen toppings. Commonly known as nori in Japan and gim in Korea, red seaweed is especially popular across Asia. Yet, despite its widespread consumption, many of its nutritional benefits remain poorly understood. Now, research led by Hokkaido University scientists has discovered that digestion of a particular red alga releases a peptide, or a small fragment of protein, with potential benefits for blood glucose control and diabetes prevention. The study was published in Food Bioscience.

Researchers developed a drug for Alzheimer's disease, and then discovered that the molecule already exists in human blood, and is found in lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment. Sergey A. Kozin and colleagues designed a peptide to interfere with the growth of amyloid-β peptide (Aβ) plaques in the brain. Preventing the formation of such plaques has been proposed as a way to prevent Alzheimer's disease or treat it in its earlier stages, in part because Aβ plaque formation is believed to precede and potentially cause the spread of toxic tau protein. Specifically, the authors sought to disrupt abnormal interactions between Aβ and zinc ions, an interaction thought to be key to the plaque formation process.

Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity. IntroductionOvarian cancer is the second most common malignancy of the female genital tract in the United States, according to the American College of Obstetricians and Gynecologists, 2017.1 In terms of mortality, it ranked eighth worldwide in 2013 and fifth in Poland in 2019 among all cancers.2,3 The high mortality rate associated with ovarian cancer is mainly due to its late diagnosis. At the time of diagnosis, two-thirds of patients present with intraperitoneal dissemination, corresponding to International Federation of Gynecology and Obstetrics (FIGO) stage III or IV.4 The most important prognostic indicator in patients with advanced-stage ovarian cancer is the volume of residual disease after cytoreductive surgery.4 The primary treatment approach remains debulking surgery. The goal of this procedure is to achieve complete cytoreduction.